Hisse Fiyatı

Tarih	Hangzhou Tigermed Consulting Co Ciro	Hangzhou Tigermed Consulting Co EBIT	Hangzhou Tigermed Consulting Co Kar Gewinn
2026e	11,33 Milyar CNY	3,25 Milyar CNY	1,89 Milyar CNY
2025e	9,68 Milyar CNY	2,76 Milyar CNY	1,62 Milyar CNY
2024e	8,35 Milyar CNY	2,35 Milyar CNY	1,37 Milyar CNY
2023	7,38 Milyar CNY	1,71 Milyar CNY	2,02 Milyar CNY
2022	7,09 Milyar CNY	1,78 Milyar CNY	2,01 Milyar CNY
2021	5,21 Milyar CNY	1,43 Milyar CNY	2,87 Milyar CNY
2020	3,19 Milyar CNY	956,70 Milyon. CNY	1,75 Milyar CNY
2019	2,80 Milyar CNY	802,80 Milyon. CNY	841,60 Milyon. CNY
2018	2,30 Milyar CNY	628,00 Milyon. CNY	472,20 Milyon. CNY
2017	1,69 Milyar CNY	423,60 Milyon. CNY	301,00 Milyon. CNY
2016	1,17 Milyar CNY	167,50 Milyon. CNY	140,70 Milyon. CNY
2015	957,00 Milyon. CNY	210,90 Milyon. CNY	156,30 Milyon. CNY
2014	624,60 Milyon. CNY	153,80 Milyon. CNY	125,50 Milyon. CNY
2013	336,50 Milyon. CNY	89,00 Milyon. CNY	94,10 Milyon. CNY
2012	254,30 Milyon. CNY	66,70 Milyon. CNY	67,70 Milyon. CNY
2011	193,30 Milyon. CNY	54,00 Milyon. CNY	47,80 Milyon. CNY
2010	122,80 Milyon. CNY	34,50 Milyon. CNY	31,70 Milyon. CNY
2009	62,80 Milyon. CNY	7,10 Milyon. CNY	7,80 Milyon. CNY

	Ciro	EBIT	Kar Gewinn
2009	62,80 Milyon. CNY	7,10 Milyon. CNY	7,80 Milyon. CNY
2010	122,80 Milyon. CNY	34,50 Milyon. CNY	31,70 Milyon. CNY
2011	193,30 Milyon. CNY	54,00 Milyon. CNY	47,80 Milyon. CNY
2012	254,30 Milyon. CNY	66,70 Milyon. CNY	67,70 Milyon. CNY
2013	336,50 Milyon. CNY	89,00 Milyon. CNY	94,10 Milyon. CNY
2014	624,60 Milyon. CNY	153,80 Milyon. CNY	125,50 Milyon. CNY
2015	957,00 Milyon. CNY	210,90 Milyon. CNY	156,30 Milyon. CNY
2016	1,17 Milyar CNY	167,50 Milyon. CNY	140,70 Milyon. CNY
2017	1,69 Milyar CNY	423,60 Milyon. CNY	301,00 Milyon. CNY
2018	2,30 Milyar CNY	628,00 Milyon. CNY	472,20 Milyon. CNY
2019	2,80 Milyar CNY	802,80 Milyon. CNY	841,60 Milyon. CNY
2020	3,19 Milyar CNY	956,70 Milyon. CNY	1,75 Milyar CNY
2021	5,21 Milyar CNY	1,43 Milyar CNY	2,87 Milyar CNY
2022	7,09 Milyar CNY	1,78 Milyar CNY	2,01 Milyar CNY
2023	7,38 Milyar CNY	1,71 Milyar CNY	2,02 Milyar CNY
2024e	8,35 Milyar CNY	2,35 Milyar CNY	1,37 Milyar CNY
2025e	9,68 Milyar CNY	2,76 Milyar CNY	1,62 Milyar CNY
2026e	11,33 Milyar CNY	3,25 Milyar CNY	1,89 Milyar CNY

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0,06	0,12	0,19	0,25	0,34	0,62	0,96	1,17	1,69	2,30	2,80	3,19	5,21	7,09	7,38	8,35	9,68	11,33
-	96,77	58,20	31,61	32,28	85,71	53,37	22,68	43,70	36,34	21,87	13,88	63,31	35,91	4,22	13,08	15,89	17,11
33,87	45,90	45,08	46,06	44,94	47,28	44,10	37,99	42,92	43,09	46,45	47,43	43,54	39,63	38,53	-	-	-
0,02	0,06	0,09	0,12	0,15	0,30	0,42	0,45	0,72	0,99	1,30	1,51	2,27	2,81	2,85	0	0	0
0,01	0,03	0,05	0,07	0,09	0,15	0,21	0,17	0,42	0,63	0,80	0,96	1,43	1,78	1,71	2,35	2,76	3,25
11,29	27,87	27,98	25,98	26,49	24,52	21,94	14,22	25,07	27,30	28,61	29,95	27,41	25,11	23,19	28,16	28,50	28,64
0,01	0,03	0,05	0,07	0,09	0,13	0,16	0,14	0,30	0,47	0,84	1,75	2,87	2,01	2,02	1,37	1,62	1,89
-	342,86	51,61	42,55	40,30	32,98	24,80	-10,26	115,00	56,81	78,18	107,97	64,32	-30,20	0,90	-32,11	17,61	16,77
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
405,20	473,00	480,00	533,60	640,80	638,10	650,00	703,30	750,30	750,30	744,80	799,00	870,96	864,89	865,32	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	2,87	0	0
0	0	0	0	0	0	0	0	0	0	0	0	188,00	0	329,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-7,00
3,00	-10,00	-16,00	-93,00	-104,00	-238,00	-462,00	-552,00	-671,00	-921,00	-1.157,00	-1.314,00	-98,00	-1.734,00	-2.420,00
0	0	0	0	0	0	0	0	0	0	0	0	-1.548,00	0	-285,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-3,00	-4,00	-15,00	-17,00	-26,00	-41,00	-59,00	-71,00	-127,00	-140,00	-234,00	-241,00	-321,00	-321,00	-594,00
0,02	0,03	0,04	0,02	0,08	0,04	0,19	0,19	0,32	0,52	0,53	1,00	1,42	1,42	1,36
-13,00	-8,00	-16,00	-21,00	-37,00	-38,00	-87,00	-61,00	-46,00	-91,00	-102,00	-156,00	-368,00	-368,00	-448,00
-34,00	-20,00	4,00	-22,00	-139,00	-219,00	-413,00	-530,00	-846,00	-366,00	-638,00	-2.367,00	-2.782,00	-2.782,00	-2.789,00
-20,00	-12,00	20,00	-1,00	-102,00	-181,00	-326,00	-468,00	-800,00	-274,00	-535,00	-2.210,00	-2.414,00	-2.414,00	-2.340,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0,23	-0,01	-0,05	0,08	0,34	0,18	-0,90	0,40	0,49	1,61
0	0	0	0	0	0	0	0	0	0	0	0	-227,00	0	-87,00
0	0,02	0	0,48	-0,04	0,12	0,01	0,49	0,70	0,01	1,43	9,34	-0,16	-0,16	0,81
0	0,02	0	0,48	0,00	-0,06	0,07	0,59	0,69	-0,20	1,52	10,51	-0,05	-0,37	-0,31
0	0	0	0	-43,00	-46,00	-46,00	-59,00	-62,00	-126,00	-266,00	-271,00	-284,00	-284,00	-491,00
0,01	0,07	0,11	0,60	0,10	0,27	0,51	0,98	1,28	1,76	3,26	10,48	1,95	1,90	3,78
8,00	18,30	22,50	-6,70	39,70	5,60	98,60	130,20	269,00	430,50	424,70	842,20	1.055,18	1.055,18	908,90
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Hangzhou Tigermed Consulting Co Brüt Marj	Hangzhou Tigermed Consulting Co Kâr Marjı	Hangzhou Tigermed Consulting Co EBIT Marjı	Hangzhou Tigermed Consulting Co Kâr Marjı
2026e	38,53 %	28,64 %	16,66 %
2025e	38,53 %	28,50 %	16,70 %
2024e	38,53 %	28,16 %	16,47 %
2023	38,53 %	23,20 %	27,42 %
2022	39,64 %	25,12 %	28,32 %
2021	43,55 %	27,42 %	55,13 %
2020	47,43 %	29,97 %	54,81 %
2019	46,48 %	28,64 %	30,02 %
2018	43,10 %	27,30 %	20,52 %
2017	42,94 %	25,11 %	17,84 %
2016	38,03 %	14,26 %	11,98 %
2015	44,12 %	22,04 %	16,33 %
2014	47,33 %	24,62 %	20,09 %
2013	45,05 %	26,45 %	27,96 %
2012	46,24 %	26,23 %	26,62 %
2011	45,11 %	27,94 %	24,73 %
2010	45,60 %	28,09 %	25,81 %
2009	34,39 %	11,31 %	12,42 %

	Brüt Marj	EBIT Marjı	Kâr Marjı
2009	34,39 %	11,31 %	12,42 %
2010	45,60 %	28,09 %	25,81 %
2011	45,11 %	27,94 %	24,73 %
2012	46,24 %	26,23 %	26,62 %
2013	45,05 %	26,45 %	27,96 %
2014	47,33 %	24,62 %	20,09 %
2015	44,12 %	22,04 %	16,33 %
2016	38,03 %	14,26 %	11,98 %
2017	42,94 %	25,11 %	17,84 %
2018	43,10 %	27,30 %	20,52 %
2019	46,48 %	28,64 %	30,02 %
2020	47,43 %	29,97 %	54,81 %
2021	43,55 %	27,42 %	55,13 %
2022	39,64 %	25,12 %	28,32 %
2023	38,53 %	23,20 %	27,42 %
2024e	38,53 %	28,16 %	16,47 %
2025e	38,53 %	28,50 %	16,70 %
2026e	38,53 %	28,64 %	16,66 %

Tarih	Hangzhou Tigermed Consulting Co Hisse başına satış	Hangzhou Tigermed Consulting Co EBIT hisse başına	Hangzhou Tigermed Consulting Co Hisse başına kar
2026e	19,90 CNY	0 CNY	3,32 CNY
2025e	16,99 CNY	0 CNY	2,84 CNY
2024e	14,66 CNY	0 CNY	2,41 CNY
2023	8,53 CNY	1,98 CNY	2,34 CNY
2022	8,19 CNY	2,06 CNY	2,32 CNY
2021	5,99 CNY	1,64 CNY	3,30 CNY
2020	4,00 CNY	1,20 CNY	2,19 CNY
2019	3,76 CNY	1,08 CNY	1,13 CNY
2018	3,07 CNY	0,84 CNY	0,63 CNY
2017	2,25 CNY	0,56 CNY	0,40 CNY
2016	1,67 CNY	0,24 CNY	0,20 CNY
2015	1,47 CNY	0,32 CNY	0,24 CNY
2014	0,98 CNY	0,24 CNY	0,20 CNY
2013	0,53 CNY	0,14 CNY	0,15 CNY
2012	0,48 CNY	0,13 CNY	0,13 CNY
2011	0,40 CNY	0,11 CNY	0,10 CNY
2010	0,26 CNY	0,07 CNY	0,07 CNY
2009	0,15 CNY	0,02 CNY	0,02 CNY

	Hisse başına satış	EBIT hisse başına	Hisse başına kar
2009	0,15 CNY	0,02 CNY	0,02 CNY
2010	0,26 CNY	0,07 CNY	0,07 CNY
2011	0,40 CNY	0,11 CNY	0,10 CNY
2012	0,48 CNY	0,13 CNY	0,13 CNY
2013	0,53 CNY	0,14 CNY	0,15 CNY
2014	0,98 CNY	0,24 CNY	0,20 CNY
2015	1,47 CNY	0,32 CNY	0,24 CNY
2016	1,67 CNY	0,24 CNY	0,20 CNY
2017	2,25 CNY	0,56 CNY	0,40 CNY
2018	3,07 CNY	0,84 CNY	0,63 CNY
2019	3,76 CNY	1,08 CNY	1,13 CNY
2020	4,00 CNY	1,20 CNY	2,19 CNY
2021	5,99 CNY	1,64 CNY	3,30 CNY
2022	8,19 CNY	2,06 CNY	2,32 CNY
2023	8,53 CNY	1,98 CNY	2,34 CNY
2024e	14,66 CNY	0 CNY	2,41 CNY
2025e	16,99 CNY	0 CNY	2,84 CNY
2026e	19,90 CNY	0 CNY	3,32 CNY

	Hisse Senedi Sayısı
2009	405,20 Milyon. Aktien
2010	473,00 Milyon. Aktien
2011	480,00 Milyon. Aktien
2012	533,60 Milyon. Aktien
2013	640,80 Milyon. Aktien
2014	638,10 Milyon. Aktien
2015	650,00 Milyon. Aktien
2016	703,30 Milyon. Aktien
2017	750,30 Milyon. Aktien
2018	750,30 Milyon. Aktien
2019	744,80 Milyon. Aktien
2020	799,00 Milyon. Aktien
2021	870,96 Milyon. Aktien
2022	864,89 Milyon. Aktien
2023	865,32 Milyon. Aktien
2024e	865,32 Milyon. Aktien
2025e	865,32 Milyon. Aktien
2026e	865,32 Milyon. Aktien

Tarih	Hangzhou Tigermed Consulting Co Temettü
2026e	0,60 CNY
2025e	0,60 CNY
2024e	0,60 CNY
2023	0,55 CNY
2022	0,50 CNY
2021	0,30 CNY
2020	0,28 CNY
2019	0,23 CNY
2018	0,13 CNY
2017	0,07 CNY
2016	0,07 CNY
2015	0,07 CNY
2014	0,07 CNY
2013	0,07 CNY

	Temettü	Tahmini Temettü
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0 CNY	0 CNY
2012	0 CNY	0 CNY
2013	0,07 CNY	0 CNY
2014	0,07 CNY	0 CNY
2015	0,07 CNY	0 CNY
2016	0,07 CNY	0 CNY
2017	0,07 CNY	0 CNY
2018	0,13 CNY	0 CNY
2019	0,23 CNY	0 CNY
2020	0,28 CNY	0 CNY
2021	0,30 CNY	0 CNY
2022	0,50 CNY	0 CNY
2023	0,55 CNY	0 CNY
2024e	0 CNY	0,60 CNY
2025e	0 CNY	0,60 CNY
2026e	0 CNY	0,60 CNY

Tarih	Hangzhou Tigermed Consulting Co Dağıtım Oranı
2026e	15,49 %
2025e	17,01 %
2024e	15,03 %
2023	14,45 %
2022	21,55 %
2021	9,09 %
2020	12,69 %
2019	20,65 %
2018	21,16 %
2017	16,67 %
2016	33,33 %
2015	27,78 %
2014	33,33 %
2013	44,44 %
2012	14,45 %
2011	14,45 %
2010	14,45 %
2009	14,45 %

	Dağıtım Oranı
2009	14,45 %
2010	14,45 %
2011	14,45 %
2012	14,45 %
2013	44,44 %
2014	33,33 %
2015	27,78 %
2016	33,33 %
2017	16,67 %
2018	21,16 %
2019	20,65 %
2020	12,69 %
2021	9,09 %
2022	21,55 %
2023	14,45 %
2024e	15,03 %
2025e	17,01 %
2026e	15,49 %

Tarih	EPS-Tahmini	EPS-Gerçeklesen	Rapor Dönemi
31.03.2024	0,54 CNY	0,27 CNY (-49,66 %)	2024 Q1
31.12.2023	0,46 CNY	0,17 CNY (-63,33 %)	2023 Q4
30.09.2023	0,75 CNY	0,57 CNY (-24,40 %)	2023 Q3
30.06.2023	0,66 CNY	0,95 CNY (44,11 %)	2023 Q2
31.03.2023	0,62 CNY	0,66 CNY (6,43 %)	2023 Q1
31.12.2022	0,63 CNY	0,46 CNY (-26,46 %)	2022 Q4
30.09.2022	0,67 CNY	0,48 CNY (-28,39 %)	2022 Q3
30.06.2022	0,65 CNY	0,78 CNY (20,23 %)	2022 Q2
31.03.2022	0,63 CNY	0,60 CNY (-5,05 %)	2022 Q1
31.12.2021	0,45 CNY	1,27 CNY (181,28 %)	2021 Q4
30.09.2021	0,41 CNY	0,61 CNY (48,94 %)	2021 Q3
30.06.2021	0,55 CNY	0,92 CNY (68,68 %)	2021 Q2
31.03.2021	0,39 CNY	0,52 CNY (32,01 %)	2021 Q1
31.12.2020	0,18 CNY	0,49 CNY (166,89 %)	2020 Q4
30.09.2020	0,35 CNY	0,39 CNY (11,62 %)	2020 Q3
30.06.2020	0,28 CNY	0,99 CNY (257,45 %)	2020 Q2
31.03.2020	0,28 CNY	0,34 CNY (21,02 %)	2020 Q1
31.12.2019	0,33 CNY	0,43 CNY (27,78 %)	2019 Q4
30.09.2019	0,22 CNY	0,23 CNY (6,48 %)	2019 Q3
30.06.2019	0,26 CNY	0,28 CNY (5,50 %)	2019 Q2
31.03.2019	0,19 CNY	0,19 CNY (-0,31 %)	2019 Q1
31.12.2018	0,18 CNY	0,21 CNY (14,65 %)	2018 Q4
30.09.2018	0,16 CNY	0,13 CNY (-19,47 %)	2018 Q3
30.06.2018	0,16 CNY	0,16 CNY (3,81 %)	2018 Q2
31.03.2018	0,12 CNY	0,13 CNY (5,47 %)	2018 Q1
31.12.2017	0,14 CNY	0,13 CNY (-5,23 %)	2017 Q4

%	Adı	Hisse senetleri	Değişim	Tarih
9,07 %	Cao (Xiaochun)	51.661.774	0	31.12.2023
5,34 %	Zhong Ou Asset Management Co., Ltd.	30.422.105	-14.368.400	31.12.2023
4,59 %	Bank of Communications Schroder Fund Management Co., Ltd.	26.125.259	-15.100	31.12.2023
31,12 %	Ye (Xiaoping)	177.239.541	0	31.12.2023
3,82 %	E Fund Management Co. Ltd.	21.780.670	821.200	31.12.2023
2,48 %	Hwabao WP Fund Management Co., Ltd.	14.118.309	-2.081.100	31.12.2023
2,18 %	Temasek Fullerton Alpha Pte. Ltd.	12.409.532	-6.681.467	31.12.2023
2,00 %	INVESCO Great Wall Fund Management Co. Ltd.	11.371.023	3.382.548	31.12.2023
1,88 %	Shi (Xiao Li)	10.678.175	0	31.12.2023
1,79 %	Zhuan (Yin)	10.220.000	0	31.12.2023
1,75 %	China Merchants Fund Management Co. Ltd.	9.962.011	-487.879	31.12.2023
1,33 %	HuaAn Fund Management Co., Ltd.	7.566.557	47.000	31.12.2023
1,32 %	Federated Hermes International	7.491.394	1.511.094	29.02.2024
1,09 %	GF Fund Management Co., Ltd.	6.191.174	1.535.900	31.12.2023
0,98 %	China Universal Asset Management Co., Ltd.	5.594.332	-322.011	31.12.2023
0,97 %	abrdn Asia Limited	5.530.194	-331.900	29.02.2024
0,96 %	Tianhong Asset Management Co., Ltd.	5.451.728	4.200	31.12.2023
0,91 %	Schroder Investment Management (Hong Kong) Ltd.	5.181.026	0	31.12.2023
0,90 %	UBS Asset Management (Hong Kong) Limited	5.101.477	0	31.12.2023
0,78 %	Harvest Fund Management Co., Ltd.	4.456.672	0	29.02.2024
0,78 %	Yinhua Fund Management Co., Ltd.	4.416.734	63.200	31.12.2023
0,73 %	Huatai-PineBridge Fund Management Co., Ltd.	4.135.631	2.002.693	31.12.2023
0,69 %	JPMorgan Asset Management (Asia Pacific) Limited	3.905.777	0	31.03.2024
0,68 %	Morgan Stanley Investment Management (China) Company Limited.	3.888.305	-754.877	31.12.2023
0,63 %	J.P. Morgan Asset Management (Singapore) Limited	3.576.156	-584.100	31.08.2022
0,53 %	China Southern Asset Management Co. Ltd.	3.031.505	-270.570	31.12.2023
0,50 %	Fullgoal Fund Management Co., Ltd.	2.871.334	-209.400	31.12.2023
0,50 %	China Asset Management Co., Ltd.	2.870.130	504.467	31.12.2023
0,39 %	Galaxy Asset Management Co., Ltd.	2.212.059	283.000	31.12.2023
0,36 %	The Vanguard Group, Inc.	2.071.736	-81.400	31.03.2024
0,36 %	Ping An Fund Management Company Limited	2.042.000	0	31.12.2023
0,34 %	Guotai Asset Management Co., Ltd.	1.951.149	-11.200	31.12.2023
0,26 %	APG Asset Management N.V.	1.506.364	-471	30.09.2023
0,21 %	Norges Bank Investment Management (NBIM)	1.199.167	-624.672	31.12.2023
0,21 %	China Fund Management Co., Ltd.	1.167.940	17.900	31.12.2023
0,20 %	Allianz Global Investors Singapore Ltd.	1.141.206	-6.136.795	31.01.2023
0,18 %	Grandeur Peak Global Advisors, LLC	1.034.068	-68.100	31.01.2024
0,18 %	ICBC Credit Suisse Asset Management Co. Ltd.	1.024.300	-400	31.12.2023
0,15 %	UBS Asset Management (UK) Ltd.	874.648	500	31.03.2024
0,15 %	Rongtong Fund Management Co., Ltd.	859.866	2.200	31.12.2023
0,14 %	Wanjia Asset Management Co., Ltd.	782.480	695.680	30.06.2023
0,13 %	Great Wall Fund Management Co., Ltd.	720.594	-1.209.441	30.06.2023
0,12 %	Bosera Asset Management Co., Ltd.	704.910	154.400	31.12.2023
0,12 %	Invesco Advisers, Inc.	691.390	0	31.10.2022
0,10 %	UBS Asset Management (Switzerland)	548.674	0	29.02.2024
0,09 %	Fidelity Management & Research (Hong Kong) Limited	537.305	-43.400	29.02.2024
0,09 %	BlackRock Institutional Trust Company, N.A.	527.141	25.900	31.03.2024
0,08 %	PengYang Asset Management Co., Ltd	478.693	-30.800	30.06.2023
0,08 %	Harvest Global Investments Limited	452.032	0	31.03.2024
0,08 %	Dacheng Fund Management Co., Ltd.	441.990	200	31.12.2023
0,08 %	Cinda Fund Management Co., Ltd.	440.762	440.762	31.12.2023
0,08 %	BlackRock Advisors (UK) Limited	434.621	16.100	31.03.2024
0,07 %	Penghua Fund Management Co., Ltd.	396.146	190.467	30.06.2023
0,07 %	Principal Global Investors (Hong Kong) Limited	382.500	382.500	31.12.2022
0,06 %	China Asset Management (Hong Kong) Limited	352.789	26.200	31.03.2024
0,06 %	Wasatch Global Investors Inc	317.238	-26.700	31.12.2023
0,05 %	Orient Securities Asset Management Company Limited	302.000	-10.417	30.06.2023
0,05 %	California State Teachers Retirement System	273.731	-120.155	30.06.2023
0,05 %	DWS Investments UK Limited	271.510	-647	31.03.2024
0,05 %	State Street Global Advisors (US)	264.539	-5.000	31.03.2024
0,05 %	Truvalue Asset Management Co., Ltd.	264.000	-757.671	30.06.2023
0,04 %	Amundi Asset Management, SAS	242.672	55.600	31.03.2024
0,04 %	Huashang Fund Management Co., Ltd.	235.000	41.300	31.12.2023
0,04 %	Capital Investment Trust Corporation	234.244	234.244	31.12.2023
0,04 %	Guotai Junan Securities Assets Management Co., Ltd.	230.500	133.600	30.06.2023
0,03 %	Mellon Investments Corporation	183.667	-5.800	31.03.2024
0,03 %	Lion Fund Management Co., Ltd.	169.594	96.000	31.12.2023
0,03 %	Matthews International Capital Management, L.L.C.	169.076	0	29.02.2024
0,03 %	SEB Asset Management (Denmark)	165.678	-168.003	29.02.2024
0,02 %	Mirae Asset Global Investments Co., Ltd.	141.758	138	31.01.2024
0,02 %	Taikang Asset Management Co., Ltd.	140.307	-4.300	30.06.2023
0,02 %	Degroof Petercam Asset Management	137.756	-12.109	31.12.2023
0,02 %	Tibet Eastmoney Fund Management Co., Ltd.	135.800	-10.700	31.12.2023
0,02 %	Western Leadbank Fund Management Co., Ltd.	132.459	68.000	30.06.2023
0,02 %	BlackRock (Singapore) Limited	131.927	29.022	31.03.2024
0,02 %	China Life AMP Asset Management Co., Ltd	131.609	4.300	31.12.2023
0,02 %	CITIC Prudential Fund Management Co., Ltd.	122.900	2.000	30.06.2023
0,02 %	Beixin Ruifeng Fund Management Co., Ltd.	121.500	23.500	31.12.2023
0,02 %	JT Asset Management Co., Ltd.	110.700	-16.600	30.06.2023
0,02 %	JPMorgan Asset Management (China) Company Limited.	108.900	8.000	30.06.2023
0,02 %	Taiping Fund Management Co., Ltd.	98.600	98.600	30.06.2023
0,02 %	Everbright PGIM Fund Management Co., Ltd.	95.225	-13.400	31.12.2023
0,02 %	CCB Principal Asset Management Co., Ltd.	91.008	-1.300	31.12.2023
0,02 %	JPMorgan Asset Management U.K. Limited	90.102	1.000	31.03.2024
0,02 %	BlackRock Investment Management, LLC	87.900	-2.200	31.12.2023
0,02 %	SWS MU Fund Management Co., Ltd.	87.291	-8.400	30.06.2023
0,02 %	Maxwealth Fund Management Co., Ltd.	85.532	20.100	30.06.2023
0,01 %	Founder Fubon Fund Management Co., Ltd.	84.900	-600	31.12.2023
0,01 %	Xingyin Fund Management Co., Ltd.	84.600	-5.900	30.06.2023
0,01 %	Geode Capital Management, L.L.C.	83.257	6.500	29.02.2024
0,01 %	Amundi Japan Ltd.	70.600	8.200	31.03.2024
0,01 %	Nikko Asset Management Asia Limited	70.394	-249.892	30.11.2023
0,01 %	Union Investment Privatfonds GmbH	69.941	-419.964	30.06.2023
0,01 %	Ninety One North America, Inc.	69.156	0	31.12.2023
0,01 %	State Street Global Advisors (UK) Ltd.	65.883	0	31.03.2024
0,01 %	CPIC Fund Management Co., Ltd.	65.398	-2.900	31.12.2023
0,01 %	Charles Schwab Investment Management, Inc.	64.700	0	31.03.2024
0,01 %	Xinjiang Qianhai Alliance Asset Management Co., Ltd.	56.100	-60.400	30.06.2023
0,01 %	Purekind Fund Management Co., Ltd.	54.600	-70.400	30.06.2023
0,01 %	CSOP Asset Management Limited	54.400	0	31.03.2024

What values and corporate philosophy does Hangzhou Tigermed Consulting Co represent?

Hangzhou Tigermed Consulting Co Ltd represents values of trust, innovation, and excellence in the field of clinical research and drug development. As a leading contract research organization, Tigermed is committed to providing high-quality services and solutions to pharmaceutical companies globally. With a strong focus on integrity and professionalism, the company aims to assist clients in achieving their clinical development goals efficiently. Moreover, Tigermed values collaboration, aiming to foster meaningful partnerships with its clients and professionals in the healthcare industry. Through cutting-edge technology and a customer-centric approach, Hangzhou Tigermed Consulting Co Ltd strives to be a reliable and strategic partner in advancing healthcare outcomes.

In which countries and regions is Hangzhou Tigermed Consulting Co primarily present?

Hangzhou Tigermed Consulting Co Ltd is primarily present in China, as it is a Chinese company. However, it also has a significant presence in other countries and regions. With its global expansion strategy, Hangzhou Tigermed Consulting Co Ltd has established branches and offices in numerous locations worldwide. These include the United States, Japan, South Korea, Europe, Australia, and Southeast Asia. This widespread presence allows Hangzhou Tigermed Consulting Co Ltd to offer its comprehensive range of pharmaceutical and clinical research services to clients internationally.

What significant milestones has the company Hangzhou Tigermed Consulting Co achieved?

Hangzhou Tigermed Consulting Co Ltd has achieved significant milestones in its history. As a leading contract research organization (CRO), the company has successfully established a global presence and expanded its service offerings. It has demonstrated its expertise in clinical research, regulatory affairs, and data management, serving clients across various therapeutic areas. Tigermed Consulting has also formed strategic partnerships with renowned pharmaceutical companies, positioning itself as a trusted partner in drug development and clinical trials. With its commitment to innovation and quality, Hangzhou Tigermed Consulting Co Ltd continues to make substantial advancements in the field of healthcare and contribute to improved patient outcomes.

What is the history and background of the company Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co Ltd is a leading contract research organization (CRO) based in China. Founded in 2004, the company has rapidly grown to become one of the largest independent CROs in the country. Tigermed specializes in providing comprehensive clinical research and development services to pharmaceutical and biotech companies globally. With a strong focus on clinical trial management, regulatory affairs, and data management, Tigermed has established a solid reputation for delivering high-quality solutions to its clients. The company's commitment to excellence and extensive experience in the industry has enabled it to forge strong partnerships and contribute significantly to the advancement of healthcare research.

Who are the main competitors of Hangzhou Tigermed Consulting Co in the market?

Some of the main competitors of Hangzhou Tigermed Consulting Co Ltd in the market include PPD Inc., ICON plc, QuintilesIMS, PAREXEL International Corporation, and Wuxi AppTec.

In which industries is Hangzhou Tigermed Consulting Co primarily active?

Hangzhou Tigermed Consulting Co Ltd is primarily active in the pharmaceutical and biotech industries.

What is the business model of Hangzhou Tigermed Consulting Co?

The business model of Hangzhou Tigermed Consulting Co Ltd revolves around providing comprehensive and integrated clinical research services to support the development and marketing of pharmaceutical, biotechnological, and medical device products. As a leading Contract Research Organization (CRO) in China, Tigermed offers a wide range of services including project planning, clinical trial management, regulatory affairs, data management, statistical analysis, and quality assurance. By leveraging their expertise, experience, and strategic partnerships, Hangzhou Tigermed Consulting Co Ltd caters to the growing needs of domestic and international clients in the healthcare industry.

Hangzhou Tigermed Consulting Co 2024’nin KGV’si nedir?

Hangzhou Tigermed Consulting Co hissesinin F/K oranı 30,63.

Hangzhou Tigermed Consulting Co 2024’nin KUV’si nedir?

Hangzhou Tigermed Consulting Co KUV 5,04 dir.

Hangzhou Tigermed Consulting Co hangi AlleAktien Kalite Skoruna sahip?

Hangzhou Tigermed Consulting Co için AlleAktien Kalite Skoru 8/10'dur.

Hangzhou Tigermed Consulting Co 2024’nin cirosu ne kadar?

beklenen Hangzhou Tigermed Consulting Co cirosu 8,35 Milyar CNY dir.

Hangzhou Tigermed Consulting Co 2024 karı ne kadar?

beklenen Hangzhou Tigermed Consulting Co karı 1,37 Milyar CNY olarak gerçekleşmiştir.

Hangzhou Tigermed Consulting Co ne yapıyor?

The Hangzhou Tigermed Consulting Co Ltd is a leading company in the field of clinical research, offering a wide range of services to its customers. The company was founded in 2004 and has its headquarters in Hangzhou, China. With offices in various cities in China, Europe, and the USA, the company now has over 800 employees worldwide. The business model of Tigermed Consulting is to support companies in developing and bringing new products to market. To this end, the company offers a wide range of services that span the entire product lifecycle. The company provides customers with support in the planning, execution, and evaluation of clinical studies, following applicable regulations and guidelines. The company specializes in clinical studies, regulatory affairs, medical devices, biostatistics, and medical writing services. Tigermed Consulting offers unique services to its customers, providing comprehensive solutions for their clinical studies, regulatory matters, and medical products. The company has experienced significant growth in recent years by offering a broad range of customizable services tailored to the specific needs of its customers. Overall, the business model of Tigermed Consulting aims to help its customers stay competitive and successfully bring their products to market. In a world driven by new technologies and innovations, it is important to leverage the expertise of companies like Tigermed Consulting to operate a successful and profitable business.

Hangzhou Tigermed Consulting Co Dividendesi ne kadar yüksek?

Hangzhou Tigermed Consulting Co, yılda kez dağıtılmak üzere 0,50 CNY tutarında temettü ödemektedir.

Hangzhou Tigermed Consulting Co ne sıklıkla temettü ödüyor?

Hangzhou Tigermed Consulting Co için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Hangzhou Tigermed Consulting Co ISIN nedir?

Hangzhou Tigermed Consulting Co şirketinin ISIN kodu CNE100001KV8’dir.

Hangzhou Tigermed Consulting Co Ticker nedir?

Hangzhou Tigermed Consulting Co için Ticker 300347.SZ’dir.

Hangzhou Tigermed Consulting Co ne kadar temettü ödüyor?

Son 12 ay içerisinde Hangzhou Tigermed Consulting Co, 0,55 CNY tutarında bir temettü ödedi. Bu, yaklaşık olarak 1,13 % oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Hangzhou Tigermed Consulting Co, tahmini olarak 0,60 CNY tutarında bir temettü ödemesi yapacak.

Hangzhou Tigermed Consulting Co’nin temettü verimi ne kadar?

Hangzhou Tigermed Consulting Co şirketinin mevcut temettü verimi 1,13 %.

Hangzhou Tigermed Consulting Co ne zaman temettü ödüyor?

Hangzhou Tigermed Consulting Co dönemsel olarak temettü ödemesi yapar. Bu ödemeler Haziran, Temmuz, Haziran, Ağustos aylarında gerçekleştirilir.

Hangzhou Tigermed Consulting Co şirketinin temettüsü ne kadar güvenli?

Hangzhou Tigermed Consulting Co, son 14 yıl içerisinde her yıl temettü ödedi.

Hangzhou Tigermed Consulting Co şirketinin temettüsü ne kadar?

Önümüzdeki 12 ay için 0,60 CNY tutarında temettü ödenmesi beklenmektedir. Bu, 1,23 % oranında bir temettü verimidir.

Hangzhou Tigermed Consulting Co hangi sektörde bulunuyor?

Hangzhou Tigermed Consulting Co, 'Sağlık' sektörüne atanmıştır.

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

Son Hangzhou Tigermed Consulting Co tarihinde 0,55 CNY tutarındaki en son temettüyü alabilmek için, hisseyi 07.07.2023 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Hangzhou Tigermed Consulting Co en son ne zaman temettü ödemesi yaptı?

Son ödeme tarihi 07.07.2023 olarak gerçekleşti.

Hangzhou Tigermed Consulting Co şirketinin 2023 yılında dağıttığı temettü miktarı ne kadardı?

2023 yılında Hangzhou Tigermed Consulting Co tarafından 0,5 CNY olarak temettüler dağıtıldı.

Hangzhou Tigermed Consulting Co hangi para biriminde temettü dağıtıyor?

Hangzhou Tigermed Consulting Co hisselerinin temettüleri CNY olarak dağıtılır.

Doğrudan Emisyonlar	110,04
Satın alınan enerjiden kaynaklanan dolaylı emisyonlar	9.810,26
Tedarik zinciri içindeki dolaylı emisyonlar	—
CO₂ Emisyonları	9.920,3
CO₂ Azaltma Stratejisi	✅
Kömür Enerjisi	❌
Atom Enerjisi	❌
Hayvan deneyleri	✅
Kürk & Deri	—
Pestisitler	—
Palm Yağı	—
Tabak	❌
Genetik Mühendisliği	❌
İklim Konsepti	—
Sürdürülebilir Ormancılık	—
Geri Dönüşüm Yönetmelikleri	❌
Çevre dostu ambalaj	❌
Tehlikeli maddeler	❌
Yakıt Tüketimi ve Verimliliği	✅
Su tüketimi ve verimliliği	✅

Kadın Çalışan Oranı	81,355
Yönetimdeki Kadınların Oranı	—
Asyalı Çalışan Oranı	—
Asyalı Yönetim Payı	—
Hispanik/Latino Çalışanların Oranı	—
Hispanik/Latino Yönetim Payı	—
Siyahi Çalışan Oranı	—
Siyahi Yönetim Oranı	—
Beyaz çalışanların oranı	—
Beyaz Yönetim Oranı	—
Yetişkin İçerikleri	❌
Alkol	❌
Savunma	—
Ateşli Silahlar	❌
Kumar	❌
Askeri Sözleşmeler	❌
İnsan Hakları Konsepti	✅
Gizlilik Politikası	—
İş ve Sağlık Güvenliği	✅
Katolik	✅

Sürdürülebilirlik Raporu	✅
Paydaş Katılımı	✅
Geri Arama Politikaları	❌
Rekabet hukuku	❌

Hangzhou Tigermed Consulting Co Ticker	Hangzhou Tigermed Consulting Co FIGI
300347:CH	BBG002PKXG01
300347:CS	BBG002QKZ361
300347:C2	BBG00F13DR59

Hayatının en iyi yatırımlarını yap fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Fiyat

Hisse Senedi Fiyatı

Ticker300347.SZ

ISINCNE100001KV8

Hangzhou Tigermed Consulting Co Hisse Senedi Ciro, EBIT, Kar CNE100001KV8 ·

Ciro, Kar & EBIT

Ciro, EBIT ve Gelir Anlayışı

Yıllık Analiz ve Karşılaştırmalar

Yatırım için Beklentileri Kullanma

Yatırım İçgörüleri

Hangzhou Tigermed Consulting Co Ciro, Kar ve EBIT Geçmişi

Hangzhou Tigermed Consulting Co Hisse Senedi Göstergeleri

GuV

Ciro ve Büyüme

Brüt Marj

EBIT ve EBIT Marjı

Gelir ve Büyüme

Dolaşımdaki Hisse Senetleri

Yıllık Kıyaslamanın Yorumlanması

Beklentiler ve Tahminler

Bilanço

Bilançonun Anlaşılması

Varlıklar

Yükümlülükler

Özsermaye

Yıl-sonu-Yıl Analizi

Verilerin Yorumlanması

Hangzhou Tigermed Consulting Co Hisse Marjları CNE100001KV8 ·

Marj

Brüt Marjı Anlamak

EBIT Marjı Analizi

Ciro Marjı İçgörüleri

Beklentileri Yorumlamak

Karşılaştırmalı Analiz

Hangzhou Tigermed Consulting Co Marjin Geçmişi

Hangzhou Tigermed Consulting Co Hisse Geliri, EBIT, Hisse Başına Kar CNE100001KV8 ·

Ciro, EBIT ve Hisse Başına Kar

Hisse Başına Ciro

Hisse Başına EBIT

Hisse Başına Gelir

Beklenen Değerler

Hangzhou Tigermed Consulting Co Ciro, Kar ve EBIT Hisse Başına Tarihçesi

Hangzhou Tigermed Consulting Co Hisse ve Hisse Analizi

Hangzhou Tigermed Consulting Co Tarihsel F/K, EBIT ve F/D oranlarına göre değerlendirme

Hangzhou Tigermed Consulting Co Adet Hisse Senedi CNE100001KV8 ·

Ciro, EBIT ve Hisse Başına Kar

Hisse Başına Ciro

Hisse Başına EBIT

Hisse Başına Gelir

Beklenen Değerler

Hangzhou Tigermed Consulting Co Hisse bölünmeleri

Hangzhou Tigermed Consulting Co Hisse Temettüsü CNE100001KV8 ·

Dividende

Dividendenler Hakkında Genel Bakış

Yorum ve Kullanım

Yatırım Stratejisi

Hangzhou Tigermed Consulting Co Temettü Geçmişi

Hangzhou Tigermed Consulting Co Hisse Dağıtım Oranı CNE100001KV8 ·

Dağıtım Oranı

Yıllık dağıtım oranı nedir?

Verilerin Yorumlanması

Yatırım İçin Veri Kullanımı

Hangzhou Tigermed Consulting Co Dağıtım Oranları Tarihi

Hangzhou Tigermed Consulting Co Kazanç Tahminleri

Hangzhou Tigermed Consulting Co Kazanç Sürprizleri

Eulerpool ESG Derecelendirmesi Hangzhou Tigermed Consulting Co Hisse için

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

👫 Social

🏛️ Governance

Çevre

Sosyal

Şirket Yönetimi (Governance)

Hangzhou Tigermed Consulting Co Hisse Yapısı

Hangzhou Tigermed Consulting Co Yönetim Kurulu ve Denetim Kurulu

Sıkça Sorulan Sorular Hangzhou Tigermed Consulting Co Hisse Senedi Hakkında

What values and corporate philosophy does Hangzhou Tigermed Consulting Co represent?

In which countries and regions is Hangzhou Tigermed Consulting Co primarily present?

Hayatının en iyi yatırımlarını yap
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
300347.SZ

ISIN
CNE100001KV8